Business Context and Reporting Period
This Form 8-K filing by Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.) is dated April 25, 2007, with the earliest event reported on May 1, 2007. The report details significant changes to the Company's Board of Directors and senior management team, including the appointment of a new Chief Executive Officer and Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- Leadership Transition: David C. Dvorak was appointed President and Chief Executive Officer, succeeding J. Raymond Elliott, who is retiring. Mr. Elliott will remain Chairman of the Board through at least November 2007.
- Board Expansion: The Board of Directors increased in size from six to seven members with the addition of Mr. Dvorak.
- CFO Change: James T. Crines was appointed Executive Vice President, Finance and Chief Financial Officer, replacing Sam R. Leno, who resigned effective May 4, 2007.
Compensation, Outlook, and Risks
The Compensation and Management Development Committee approved new compensation packages effective May 1, 2007:
- Base Salaries: Mr. Dvorak's salary was set at $700,000 annually; Mr. Crines' salary was set at $415,000 annually.
- Performance Incentives: Target annual cash incentive awards are 100% of base salary for Mr. Dvorak and 60% for Mr. Crines. Performance goals for 2007 are weighted 50% on earnings per share, 25% on revenue, and 25% on cash flow.
- Equity Awards (Mr. Dvorak):
- 100,000 non-qualified stock options vesting ratably over four years.
- Performance shares with a target of 19,000 (maximum 57,000) for the period ending December 31, 2008.
- Restricted shares with a grant date fair market value of $2,000,000, vesting ratably over years three, four, and five.
- Equity Awards (Mr. Crines):
- 25,000 non-qualified stock options vesting ratably over four years.
- Performance shares with a target of 4,445 (maximum 13,334) for the period ending December 31, 2008.
- Restricted shares with a grant date fair market value of $1,000,000, vesting ratably over years three, four, and five.
Both executives retain existing change in control severance agreements and non-compete/non-solicitation agreements as described in the 2007 proxy statement.
Investor Verification Checklist
- Verify the specific performance conditions for the performance share awards, which were to be approved by the Committee within 90 days of the grant date.
- Review the 2007 proxy statement for details on the defined benefit pension plan, 401(k) plan, and supplemental plans applicable to the new executives.
- Confirm the terms of the change in control severance agreements referenced in the filing.
- Monitor future filings for the formal award agreements regarding the performance shares.